Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$4.9 million.

  • Gain Therapeutics' Free Cash Flow rose 1892.25% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.3 million, marking a year-over-year increase of 1791.81%. This contributed to the annual value of -$18.9 million for FY2024, which is 7.99% down from last year.
  • According to the latest figures from Q3 2025, Gain Therapeutics' Free Cash Flow is -$4.9 million, which was up 1892.25% from -$5.1 million recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Free Cash Flow ranged from a high of -$2.2 million in Q3 2021 and a low of -$6.1 million during Q3 2024
  • In the last 5 years, Gain Therapeutics' Free Cash Flow had a median value of -$4.0 million in 2023 and averaged -$4.2 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 66378.13% in 2021, then soared by 3895.16% in 2024.
  • Gain Therapeutics' Free Cash Flow (Quarter) stood at -$4.2 million in 2021, then grew by 5.86% to -$3.9 million in 2022, then crashed by 44.62% to -$5.7 million in 2023, then surged by 38.95% to -$3.5 million in 2024, then plummeted by 42.56% to -$4.9 million in 2025.
  • Its Free Cash Flow stands at -$4.9 million for Q3 2025, versus -$5.1 million for Q2 2025 and -$3.8 million for Q1 2025.